Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 001-41264 NUVECTIS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 86-2405608 (State or Other ...

Financial Performance - The net loss for the first quarter of 2025 was $5.3 million, compared to a net loss of $4.2 million for the same period in 2024, representing an increase of $1.1 million [4]. - The basic and diluted net loss per common share outstanding was $0.27 for the first quarter of 2025, compared to $0.25 for the same period in 2024 [15]. Cash and Assets - Cash and cash equivalents increased to $29.9 million as of March 31, 2025, from $18.5 million as of December 31, 2024, reflecting a $11.4 million increase due to a public offering [3]. - The total assets as of March 31, 2025, were $30.1 million, compared to $18.6 million as of December 31, 2024 [13]. - The total liabilities as of March 31, 2025, were $9.2 million, unchanged from December 31, 2024 [13]. - The company completed a financing round of $15.5 million, extending its cash runway into the first quarter of 2027 [5]. Expenses - Research and development expenses rose to $3.7 million for the first quarter of 2025, up from $2.7 million in the same quarter of 2024, an increase of approximately 37% [6]. - General and administrative expenses were $1.9 million for the first quarter of 2025, compared to $1.7 million for the same period in 2024, an increase of about 11.8% [6]. Clinical Development - NXP900 demonstrated a robust pharmacodynamic response and acceptable safety profile in the Phase 1a dose escalation study, with plans to enter Phase 1b for specific genetic alterations [2]. - The company is advancing two clinical-stage drug candidates, NXP800 and NXP900, targeting serious conditions in oncology [8].

Core Viewpoint - Nuvectis Pharma, Inc. is advancing its clinical programs, particularly NXP900 and NXP800, while reporting a financial update for Q1 2025, highlighting increased cash reserves and ongoing clinical trials [2][3][4]. Financial Results - Cash and cash equivalents increased to $29.9 million as of March 31, 2025, from $18.5 million as of December 31, 2024, due to a public offering that generated net proceeds of $14.0 million [3]. - The net loss for Q1 2025 was $5.3 million, compared to a net loss of $4.2 million in Q1 2024, reflecting an increase of $1.1 million [4]. - Research and development expenses rose to $3.7 million in Q1 2025 from $2.7 million in Q1 2024, an increase of $1.0 million [5]. - General and administrative expenses were $1.9 million for Q1 2025, up from $1.7 million in Q1 2024, an increase of $0.2 million [5]. Clinical Development Updates - NXP900 is in the Phase 1a dose escalation study, showing a robust pharmacodynamic response and acceptable safety profile in patients with advanced cancers [2][8]. - The Phase 1b study for NXP900 will enroll patients with specific genetic alterations to evaluate its therapeutic potential [2]. - NXP800 is currently in a Phase 1b study for platinum-resistant, ARID1a mutated ovarian cancer, with updates expected in the coming months [2][8]. Company Overview - Nuvectis Pharma focuses on developing innovative precision medicines for serious oncology conditions, with two clinical-stage drug candidates: NXP800 and NXP900 [7]. - NXP800 is an oral small molecule GCN2 activator, while NXP900 is an oral small molecule inhibitor targeting SRC Family of Kinases [7][9].

Core Insights - Nuvectis Pharma, Inc. has provided updates on the Phase 1a dose-escalation study of NXP900, indicating robust pharmacodynamic responses and an acceptable safety profile with no dose limiting toxicity identified up to 250 mg/day [1][5][6] - The company is preparing to initiate the Phase 1b program, focusing on biomarker-selected cancers and evaluating NXP900 in combination with leading therapies for resistant non-small cell lung cancer (NSCLC) [4][5] Group 1: Clinical Study Highlights - NXP900 demonstrated systemic exposure that increased with dosage, achieving clinically relevant concentrations starting at 150 mg/day, with over 90% SRC inhibition observed in patient samples after a single dose [6] - The study included 29 patients with advanced cancers, with a median age of 62 years, where common treatment-emergent adverse events were mostly Grade 1-2 [6] Group 2: Preclinical Data and Rationale - Preclinical data supports NXP900's potential as a single agent and in combination with existing therapies to overcome resistance in NSCLC, particularly targeting YES1 gene amplifications and Hippo pathway alterations [1][3][4] - The addition of NXP900 to market-leading EGFR and ALK inhibitors reversed resistance, highlighting its potential in addressing unmet clinical needs in NSCLC [6] Group 3: Company Overview - Nuvectis Pharma, Inc. is focused on developing innovative precision medicines for oncology, with NXP900 being an oral small molecule inhibitor of the SRC Family of Kinases [7] - The company is also developing another candidate, NXP800, for different cancer indications, showcasing a diverse pipeline in oncology [7]

Core Viewpoint - Nuvectis Pharma, Inc. is advancing its clinical-stage drug candidate NXP900, a novel YES1/SRC kinase inhibitor, with upcoming presentations at the 2025 American Association for Cancer Research Meeting, highlighting its potential in treating advanced solid tumors and overcoming drug resistance in non-small cell lung cancer (NSCLC) [1][2]. Group 1: NXP900 Development - NXP900 is currently in a Phase 1a dose escalation study, demonstrating potent single-agent activity and synergy with ALK inhibitors in ALK-resistant NSCLC models [2][4]. - The drug targets YAP1 signaling in NSCLC cell lines and shows sensitivity in endocrine therapy-resistant luminal A breast cancer cell lines [2][4]. Group 2: Presentation Details - Nuvectis will present findings related to NXP900 in various sessions at the 2025 AACR Meeting, including "First-in-Human Phase I Clinical Trials" and "Drug Resistance in Molecular Targeted Therapies," scheduled for April 29th [3]. - Specific presentation times include sessions from 9:00 AM to 12:00 PM and 2:00 PM to 5:00 PM on the same day [3]. Group 3: Company Overview - Nuvectis Pharma, Inc. focuses on developing innovative precision medicines for serious unmet medical needs in oncology, with two clinical-stage candidates: NXP800 and NXP900 [4]. - NXP800 is an oral small molecule GCN2 activator in trials for platinum-resistant ovarian carcinoma and cholangiocarcinoma, while NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases [4].

FORT LEE, NJ, March 14, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference taking place March 17th-19th in Dana Point, California. Event37th Annual Roth ConferenceDateMarch 17, 2025Tim ...

Core Insights - Nuvectis Pharma, Inc. announced a new publication demonstrating that the combination of NXP900 and osimertinib is superior to osimertinib alone in treating EGFR-mutated non-small cell lung cancer (NSCLC) [1] - The study showed decreased cell proliferation and increased apoptosis in vitro, supporting the rationale for combining NXP900 with EGFR inhibitors [1] - Nuvectis is progressing towards the initiation of the Phase 1b program for NXP900, with a Phase 1a dose escalation study nearing completion [2] Company Overview - Nuvectis Pharma is focused on developing innovative precision medicines for serious unmet medical needs in oncology, currently working on two clinical-stage drug candidates: NXP800 and NXP900 [3] - NXP800 is in a Phase 1b clinical trial for platinum-resistant, ARID1a-mutated ovarian carcinoma, while NXP900 is an oral small molecule inhibitor of SRC Family Kinases, currently in a Phase 1a dose escalation study [3]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to . Commission File Number 001-41264 NUVECTIS PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 86-2405608 (State or Other Juris ...

Financial Performance - Nuvectis reported a net loss of $19.0 million for the year ended December 31, 2024, a decrease of $3.3 million compared to a net loss of $22.3 million in 2023[6]. - The basic and diluted net loss per common share was $1.11 for 2024, compared to $1.43 for 2023[15]. - The total stockholders' equity decreased to $9.7 million as of December 31, 2024, from $12.2 million in 2023[13]. Expenses - Research and development expenses were $12.9 million for 2024, down from $15.4 million in 2023, reflecting a decrease of $2.5 million[6]. - General and administrative expenses decreased to $6.9 million in 2024 from $7.5 million in 2023, a reduction of $0.6 million[7]. - Interest income increased to $0.8 million in 2024, compared to $0.6 million in 2023, marking an increase of $0.2 million[7]. Cash Position - Cash and cash equivalents as of December 31, 2024, were $18.5 million, a slight decrease from $19.1 million as of December 31, 2023[5]. - The company completed a follow-on offering in February 2025, raising $15.5 million in gross proceeds, extending its cash runway into 2027[4]. Clinical Trials - NXP800 is currently in a Phase 1b clinical trial for ARID1a-deficient ovarian cancer, with updated results expected in Q2 2025[4]. - Enrollment for the NXP900 Phase 1a dose escalation study is ongoing, with plans to start the Phase 1b program in mid-2025[4].

NXP800 Phase 1b study in patients with platinum resistant, ARID1a-mutated ovarian cancer is ongoing; Orphan Drug Designation granted by the U.S. FDA. Updated Phase 1b results anticipated in Q2 2025NXP900 Phase 1a dose escalation study continues to enroll, preparation for the start of the Phase 1b program is underway. Phase 1b program expected to begin in mid-2025Follow-on offering completed in February 2025 extends cash runway into 2027 FORT LEE, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ...